statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat reports...

Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Average Target Price from Analysts

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 26.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

Editas Medicine, Inc. (NASDAQ:EDIT  Free Report)  Analysts at Zacks Research decreased their Q1 2024 earnings estimates for Editas Medicine in a research note issued on Wednesday...

Q1 2024 EPS Estimates for Editas Medicine, Inc. Decreased by Zacks Research (NASDAQ:EDIT)

Investors in Editas Medicine Inc (EDIT) saw new options begin trading this week, for the May 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options...

First Week of EDIT May 3rd Options Trading

Editas Medicine, Inc. (NASDAQ:EDIT  Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 13,520,000...

Editas Medicine, Inc. (NASDAQ:EDIT) Sees Large Growth in Short Interest

Editas Medicine (NASDAQ:EDIT  Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA  Get Free Report) are both small-cap medical companies, but which is the superior stock? We will...

Head-To-Head Survey: Editas Medicine (NASDAQ:EDIT) and Taysha Gene Therapies (NASDAQ:TSHA)

This is a Bearish indicator signaling EDIT's price could decline from here. Traders may explore shorting the stock or put options...

Editas Medicine (EDIT, $8.6) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 12, 2024

This is a signal that EDIT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Editas Medicine (EDIT, $8.6) Stochastic Oscillator left the oversold zone on March 12, 2024

This indicator may be signaling that EDIT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Editas Medicine (EDIT, $8.6) entered Downtrend as Momentum indicator drops below 0 level on Mar 12, 2024

We wouldn't blame Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders if they were a little worried about the fact that...

Editas Medicine President Gilmore O'Neill Sells 45% Of Holding

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Volume	377,072.00
52-Wk High	$11.91
52-Wk Low	$5.11

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.63	--	--	N/A
Q4'23	-$0.59	-$0.23	61.31%	BEAT
Q3'23	-$0.58	-$0.55	4.36%	BEAT
Q2'23	-$0.77	-$0.56	26.98%	BEAT
Q1'23	-$0.78	-$0.71	9.45%	BEAT

EDIT Editas Medicine Inc

About

Feed

News

Sentiment

Earnings

Fundamentals